Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts

REM sleep behavior disorder (RBD) is a well-established prodromal manifestation of synucleinopathy and is closely linked to peripheral clinical features in Parkinson disease (PD). Dermal α-synuclein seed amplification assay (SAA) provides a peripheral measure of pathological α-synuclein across these disease stages. We performed a cross-sectional analysis of data from the Parkinson's Precision Medicine Initiative (PPMI), including controls, participants with polysomnography-confirmed RBD, and participants with PD. Skin SAA positivity and participant-level kinetic measures (area under the curve [AUC], maximum fluorescence [Fmax], and time to threshold [TTT]) were assessed at 1:20 and 1:50 lysate dilutions. Participants with PD were further classified as suspected brain/motor-enriched or body/peripheral-enriched based on prespecified exploratory clinical features. Skin SAA positivity was detected in 53.3% of participants with polysomnography-confirmed RBD compared with none of the controls, and RBD participants showed significantly faster amplification than controls at both lysate dilutions. Within PD, binary SAA positivity was higher in the suspected body/peripheral-enriched than brain/motor-enriched phenotype, but the difference was not statistically significant (83.3% vs 47.6%; p = 0.067). All seven kinetic measures were greater in the suspected body/peripheral-enriched phenotype after false discovery rate correction, but these differences were not retained when RBDSQ total score was removed from the classification. RBDSQ total score was the only clinical variable associated with skin SAA kinetics after correction and was significantly associated with six of the seven kinetic measures. These findings show that dermal α-synuclein seeding is detectable in PSG-confirmed prodromal RBD and is associated with RBD-related clinical features within established PD.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-20
DOI
https://doi.org/10.1371/journal.pone.0357868
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts

Emadoddin Kazemi
2 links
PLoS ONE
Parkinson's Disease Mechanisms and Treatments
article

Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts

Emadoddin Kazemi
article en

Abstract

REM sleep behavior disorder (RBD) is a well-established prodromal manifestation of synucleinopathy and is closely linked to peripheral clinical features in Parkinson disease (PD). Dermal α-synuclein seed amplification assay (SAA) provides a peripheral measure of pathological α-synuclein across these disease stages. We performed a cross-sectional analysis of data from the Parkinson's Precision Medicine Initiative (PPMI), including controls, participants with polysomnography-confirmed RBD, and participants with PD. Skin SAA positivity and participant-level kinetic measures (area under the curve [AUC], maximum fluorescence [Fmax], and time to threshold [TTT]) were assessed at 1:20 and 1:50 lysate dilutions. Participants with PD were further classified as suspected brain/motor-enriched or body/peripheral-enriched based on prespecified exploratory clinical features. Skin SAA positivity was detected in 53.3% of participants with polysomnography-confirmed RBD compared with none of the controls, and RBD participants showed significantly faster amplification than controls at both lysate dilutions. Within PD, binary SAA positivity was higher in the suspected body/peripheral-enriched than brain/motor-enriched phenotype, but the difference was not statistically significant (83.3% vs 47.6%; p = 0.067). All seven kinetic measures were greater in the suspected body/peripheral-enriched phenotype after false discovery rate correction, but these differences were not retained when RBDSQ total score was removed from the classification. RBDSQ total score was the only clinical variable associated with skin SAA kinetics after correction and was significantly associated with six of the seven kinetic measures. These findings show that dermal α-synuclein seeding is detectable in PSG-confirmed prodromal RBD and is associated with RBD-related clinical features within established PD.

PLoS ONEVol. 21(11)
Arak University of Medical Sciences (IR)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon